Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew Roughton is active.

Publication


Featured researches published by Andrew Roughton.


Bioorganic & Medicinal Chemistry Letters | 2011

Structure–activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonists

Ronald Palin; Lynn Abernethy; Nasrin Ansari; Ken Cameron; Thomas R. Clarkson; Maureen Dempster; David Dunn; Anna-Marie Easson; Darren Edwards; John Maclean; Katy Everett; Helen Feilden; Koc-Kan Ho; Steve Kultgen; Peter Littlewood; Duncan McArthur; Deborah McGregor; Hazel McLuskey; Irina Neagu; Stuart Neale; Lesley-Anne Nisbet; Michael Ohlmeyer; Quynhchi Pham; Paul Ratcliffe; Yajing Rong; Andrew Roughton; Melanie Sammons; Robert Swanson; Heather Tracey; Glenn Walker

Optimisation of a screening hit incorporating both TRPV1 activity and solubility was conducted. Substitution of the isoxazole-3-carboxamide with the bespoke 1S, 3R-3-aminocyclohexanol motif afforded the requisite balance of potency and solubility. Compounds 32 and 40 were found to have antihyperalgesic effects in the rat CFA Hg assay and induce a mechanism based hyperthermia.


Bioorganic & Medicinal Chemistry Letters | 2009

Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model

Koc-Kan Ho; James R. Beasley; Laura Belanger; Darcey Black; Jui-Hsiang Chan; David Dunn; Bing Hu; Anthony E. Klon; Steven G. Kultgen; Michael Ohlmeyer; Susan M. Parlato; Peter C. Ray; Quynhchi Pham; Yajing Rong; Andrew Roughton; Tiffany L. Walker; Jane Wright; Kai Xu; Yan Xu; Limei Zhang; Maria L. Webb

The profile of a series of triazine and pyrimidine based ROCK inhibitors is described. An initial binding mode was established based on a homology model and the proposed interactions are consistent with the observed SAR. Compounds from the series are potent in a cell migration assay and possess a favorable kinase selectivity. In vivo activity was demonstrated for compound 1A in a spontaneous hypertensive rat model.


Bioorganic & Medicinal Chemistry Letters | 2011

Discovery of potent, soluble and orally active TRPV1 antagonists. Structure-activity relationships of a series of isoxazoles.

Paul Ratcliffe; Lynn Abernethy; Nasrin Ansari; Kenneth S. Cameron; Tom Clarkson; Maureen Dempster; David Dunn; Anna-Marie Easson; Darren Edwards; Katy Everett; Helen Feilden; Koc-Kan Ho; Steve Kultgen; Peter Littlewood; John Maclean; Duncan McArthur; Deborah McGregor; Hazel McLuskey; Irina Neagu; Olaf Nimz; Lesley-Anne Nisbet; Michael Ohlmeyer; Ronnie Palin; Quynhchi Pham; Yajing Rong; Andrew Roughton; Melanie Sammons; Robert Swanson; Heather Tracey; Glenn Walker

Systematic optimisation of a poorly soluble lead series of isoxazole-3-carboxamides was conducted. Substitution of the 4-position with specific polar functionality afforded the requisite balance of potency, solubility and physicochemical properties. Compound 21a was found to be efficacious in the rat Capsaicin Hargreaves assay following oral administration.


Archive | 2008

ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS

Andrew Roughton; Yajing Rong; Koc-Kan Ho; Michael J. Ohlmeyer; David J. Diller; Ray Jui-Hsiang Chan; Gaifa Lai


Bioorganic & Medicinal Chemistry Letters | 2006

Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists

Koc-Kan Ho; Douglas S. Auld; Adolph C. Bohnstedt; Paolo Conti; Wim Dokter; Shawn David Erickson; Daming Feng; Jim Inglese; Celia Kingsbury; Steven G. Kultgen; Rong-Qiang Liu; Christopher M. Masterson; Michael Ohlmeyer; Yajing Rong; Martijn Rooseboom; Andrew Roughton; Philippe Samama; Martin-Jan Smit; Ellen Son; Jaap van der Louw; G.M.T. Vogel; Maria L. Webb; Jac Wijkmans; Ming You


Archive | 2007

Purinones and 1H-imidazopyridinones as PKC-theta inhibitors

Andrew Roughton; Yajing Rong; Koc Kan Ho; Michael Ohlmeyer; David J. Diller


Archive | 2004

Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators

Der Louw Jaap Van; Michael Ohlmeyer; Adolph C. Bohnstedt; Koc-Kan Ho; Douglas S. Auld; Steven G. Kultgen; Andrew Roughton


Archive | 2004

(2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS

Paolo Giovanni Martino Conti; Dirk Leysen; Valere X. H. Lounnas; Michael Ohlmeyer; Adolph C. Bohnstedt; Koc-Kan Ho; Steven G. Kultgen; Andrew Roughton; Douglas S. Auld


Archive | 2008

N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES

Koc-Kan Ho; Andrew Roughton; Irina Neagu; Jui-Hsiang Chan; Nasrin Ansari; Michelle Lee Morris; Yajing Rong; Michael Ohlmeyer; Andrew John Cooke; Andrew Stanley Edwards; David Jonathan Bennett


Archive | 2009

DERIVES DE PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE EN TANT QU'INHIBITEURS DE PKC-THETA

Andrew Roughton; Koc-Kan Ho; Michael Ohlmeyer; David J. Diller; Irina Neagu; Celia Kingsbury; Jui-Hsiang Chan; Johannes Petrus Maria Lommerse; Neeltje Miranda Teerhuis; Jacobus Cornelis Henricus Maria Wijkmans; Ralf Plate

Collaboration


Dive into the Andrew Roughton's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge